Value Proposition:
· A synthetic antimicrobial peptide (AMP) that may be a potent therapeutic for irritable bowel syndrome (IBS) pain.
· This AMP limits the growth of harmful bacteria, while not interfering with beneficial ones.
· This AMP can be delivered directly to the colon, bypassing any degradation by the upper gastrointestinal tract and allowing for localized effects.
Technology Description
· Researchers at Johns Hopkins have demonstrated that a synthetic AMP has potential as a treatment for IBS pain.
· Previous studies demonstrate that this AMP modulates oral microbiota in vitro and in humans.
· Preclinical research suggests that delivery of this AMP directly to the colon can reduce IBS symptoms in animal models.
Unmet Need
· Irritable Bowel Syndrome (IBS) is a chronic, episodic gastrointestinal disorder that is characterized by abdominal pain and altered bowel habit.
· The current standard of care for IBS is based on dietary modifications and medications to manage the symptoms of the disorder.
· However, these treatments have limited efficacy. Antibiotics have been previously studied for the treatment of IBS, but there is some evidence of antibiotics potentially worsening symptoms in the long run by altering the gut microbiome composition.
· Therefore, there is a strong need to develop an IBS therapeutic with higher efficacy and lower adverse effects.
Stage of Development
· The peptide has been in a Phase 2 trial for a separate indication, and has been studied in mouse for IBS pain.
Publication
· WO 2022/055993
